Massive Bio and Optellum partner on early NSCLC detection and trials

Massive Bio and Optellum have formed a partnership to integrate early detection of NSCLC with access to clinical trials. The collaboration enables clinicians to receive timely information about relevant clinical trials for patients flagged as higher risk. Optellum analyses radiology findings and CT scans to identify patients with high-risk lung nodules. Credit: NMK-Studio / Shutterstock.com. Massive Bio and Optellum have formed a partnership to integrate early detection of non-small cell lung cancer (NSCLC) with access to clinical trials. The collaboration integrates Optellum’s Lung Cancer Prediction (LCP) AI solution with Massive Bio’s AI-driven clinical trial matching technology. LOA and PTSR Model…

Source: Clinical Trials Arena